北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学药学院  > 药剂学系  > 期刊论文
学科主题: 药学
题名:
Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: In vitro and in vivo studies
作者: Zhang, Yi-fei2; Wang, Jian-cheng1,2; Bian, Dong-yan2,3; Zhang, Xuan2; Zhang, Qiang1,2
关键词: Combination therapy ; Liposomes ; Targeting ; Combretastatin A-4 ; Doxorubicin
刊名: EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
发表日期: 2010-03-01
DOI: 10.1016/j.ejpb.2010.01.002
卷: 74, 期:3, 页:467-473
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Pharmacology & Pharmacy
研究领域[WOS]: Pharmacology & Pharmacy
关键词[WOS]: ANTITUMOR EFFICACY ; CELLS ; CHEMOTHERAPY ; PHOSPHATE ; AGENTS ; DRUGS ; ANGIOGENESIS ; VASCULATURE ; COMBINATION ; INDUCTION
英文摘要:

Arg-Gly-Asp (RGD) modified doxorubicin-loaded liposomes could Improve anticancer effect, and vascular disrupting agents (VDAs) could induce a rapid and selective shutdown of the blood vessels of tumors We propose that RGD-modified liposomes for co-encapsulation and sequential release of vascular disrupting agent combretastatin A-4 (CA-4) and cytotoxic agent doxorubicin (Dox) could enhance tumor inhibition responses In this study, we encapsulated Dox and CA-4 in RGD-modified liposomes The release are of Dox was proved to be much slower than that of CA-4 in vitro Flow cytometry and laser confocal scanning microscopy clearly showed that RGD-modification promoted intracellular uptake of liposomal drugs by B16/B16F10 melanoma tumor cells and human umbilical vein endothelial cells (HUVECs) Cytotoxicity assay showed that the IC(50) of RGD-modified liposomes was lower than that of the corresponding unmodified liposomes Therapeutic benefits were examined on B16F10 melanoma tumors subcutaneously glowing in C57BL/6 mice In vivo study demonstrated that RGD-modified liposomes exhibited the most pronounced tumor regression effect when both CA-4 and Dox were co-encapsulated These results suggest that the targeted drug delivery system for co-encapsulation of vascular disrupting agents and anticancer agents may be a promising strategy for cancer treatment (c) 2010 Elsevier B.V All rights reserved

语种: 英语
所属项目编号: 2007AA021811 ; 200703935800 ; 2009z09310-001
项目资助者: National High Technology Research and Development Program of China ; National Basic Research Program of China ; National Key Program of New Drug innovation
WOS记录号: WOS:000276426200007
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/53617
Appears in Collections:北京大学药学院_药剂学系_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Dept Pharmaceut, Sch Pharmaceut Sci, Beijing 100083, Peoples R China
2.Peking Univ, Hlth Sci Ctr, State Key Lab Nat & Bromimet Drugs, Beijing 100083, Peoples R China
3.Shen Yang Pharmaceut Univ, Dept Pharmaceut, Shenyang, Peoples R China

Recommended Citation:
Zhang, Yi-fei,Wang, Jian-cheng,Bian, Dong-yan,et al. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: In vitro and in vivo studies[J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS,2010,74(3):467-473.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Zhang, Yi-fei]'s Articles
[Wang, Jian-cheng]'s Articles
[Bian, Dong-yan]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Zhang, Yi-fei]‘s Articles
[Wang, Jian-cheng]‘s Articles
[Bian, Dong-yan]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace